Tango Therapeutics Inc (TNGX)

$TNGX What's next ? See ya on November 19th ?

$TNGX Down 8.5% today to $7.67. You have a fiendish idea of “looking good”!

$TNGX Looking good. Target 14.

Stocks to watch today! $SGMT, $TNGX and $ADI

$TNGX Very strong volume today. Bodes well for near term advance.

$TNGX WITHIN THE NEXT DAY OR 2, THIS SHOULD BE TESTING SOMEWHERE BETWEEN $10-11 IF THE VOLUME CAN MAINTAIN AND WE DONT FALL BACK UNDER $8.30ISH - @DellaWeiss A PRINT?

$TNGX Expect a print

$TNGX massive Volume Spike! In this stock is generating a lot of buzz today!

$TNGX there it goes… Adding 🚨SDA🚨as I’m hearing they will be announcing something soon I am even willing to use my COIN TSLA profits into SDA

$TNGX UP 6% FROM BELL AND OVER 9% FROM PRE MARKET. THIS IS GOING TO GIVE MORE TODAY. HANG ON FOR THE RIDE! $MSRP $ENGN $SRDX $XBIT $PUBM

$TNGX BEEN RIDING SUPPORT FOR OVER A WEEK, JUST WAITING FOR THIS TO PUSH UP TO RESISTANCE. WILL BE A NICE PUSH, COMING SOON!! $MSPR $SRDX $QNRX $NRGV

$SLRX $TNGX $SNBR $SONN $BNBX GAMESQUARE = $ GAME 5 DAYS TO COVER https://fintel.io/ss/us/game

Looking for the next parabolic runner?? Make sure to keep eyes on ticker VEEE .💎 VEEE catching serious attention after that $4.X.25M property sale. Tiny float✅ Clean balance sheet✅ Not many tickers trading under $3.X with real assets and no debt VEE is one💎 The setup here is one of a kind, this has the look to go massive. Make sure not to miss out tomorrow bulls! $TNGX $TNMG $EZGO $LXEH ..61

Was there a conference call? Can anyone provide a link? I bought some $TNGX at $7.78 recently.

$TNGX "Today, 9:06 AM Tango Therapeutics reported third quarter 2025 financial results today, highlighting a return to profitability and the conclusion of its Gilead collaboration research activities."

$TNGX lets hope for a good report!! "Tango Therapeutics Inc (NASDAQ:TNGX) 12 Month Price Targets Based on the one-year price targets offered by 8 analysts, the average target price for Tango Therapeutics Inc (NASDAQ:TNGX) is $12.13 with a high estimate of $15.00 and a low estimate of $8.00. The average target implies an upside of 49.51% from the current price of $8.11. Based on GuruFocus estimates, the estimated GF Value for Tango Therapeutics Inc (NASDAQ:TNGX) in one year is $2.78, suggesting a downside of -65.72% from the current price of $8.11. Based on the consensus recommendation from 9 brokerage firms, Tango Therapeutics Inc's (NASDAQ:TNGX) average brokerage recommendation is currently 1.6, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell."

$TNGX "Heads up alert! Only three days until Upcoming earnings on Tuesday, 11/4/2025 for $TNGX Bullish (8.2) Tango Therapeutics (TNGX) has recently demonstrated strong momentum, bolstered by significant advancements in its clinical trials and strategic financing activities. The company reported promising results from its Phase 1/2 trial of Vopimetostat, particularly in treating MTAP-deleted cancers, showcasing a median progression-free survival of 7.2 months and an objective response rate of 25%. This positive clinical data, combined with a successful financing round totaling $225 million, has positioned Tango favorably for ongoing research and development. The average price target from analysts suggests a potential upside of 52.2%, reflecting optimism about the company's future earnings prospects. TNGX has also received an upgrade to a Zacks Rank #2 (Buy), indicating heightened confidence among analysts regarding its growth potential. The stock has experienced a remarkable year-to-date increase of over 170%, although it recently faced a minor pullback of 9%. Nevertheless, the overall sentiment remains bullish as investors anticipate further developments in Tango's oncology pipeline. In terms of financial metrics, Tango Therapeutics is currently focusing on expanding its clinical pipeline, which may lead to future revenue growth. While specific figures such as P/E ratio and EPS growth are not disclosed in the recent reports, the company’s ability to secure substantial financing and its positive clinical outcomes suggest it is on a solid path towards achieving profitability. Comparatively, TNGX's performance in the biotechnology sector aligns with broader industry trends, which have seen varied responses amid regulatory changes and market dynamics. The health care sector, in general, has experienced some softness, as indicated by a slight decline in the NYSE Health Care Index; however, TNGX's developments stand in contrast to this trend, highlighting its potential resilience and attractiveness to investors. Regarding upcoming earnings reports, analysts are keenly focused on Tango's performance in light of its recent clinical successes and capital raises. Historical performance indicates a pattern of volatility tied to clinical trial outcomes and financing announcements. The consensus estimates suggest that analysts expect continued improvement in earnings as the company progresses with its trials and potentially brings products to market. The anticipated earnings report is likely to reflect these dynamics, with analysts closely monitoring the impact of clinical data on revenue forecasts and overall market sentiment towards TNGX. Overall, the biotechnology sector continues to evolve, with TNGX emerging as a notable player amidst broader industry fluctuations. The company's strategic initiatives and clinical advancements position it well for sustained growth and investor interest in the near term. - Funds were net buyers of $TNGX during the previous reporting quarter. - Funds with large holdings in $TNGX include: - EcoR1 Capital LLC, MV: $54MM. Fund Rank: 56% ecor1cap.com - Farallon Capital Management LLC, MV: $47MM. Fund Rank: 70% www.faralloncapital.com - Adage Capital P, MV: $30MM. New position. Fund Rank: 89% www.adagecapital.com - Nantahala Capital Management LLC, MV: $18MM. Fund Rank: 62% www.nantahalapartners.com - RA Capital Management LLC, MV: $10MM. New position. Fund Rank: 60% www.racap.com - Last 10 days performance: -6% - Last 30 days performance: 5% - Last 90 days performance: 24% Some of the latest news articles: - Title: Wall Street Analysts Think Tango Therapeutics (TNGX) Could Surge 52.2%: Read This Before Placing a Bet Publication Date: 10/31/2025 1:55:02 PM, Source: yahoo URL: https://finance.yahoo.com/news/wall-street-analysts-think-tango-135502961.html?.tsrc=rss - Title: Why Tango Therapeutics (TNGX) Surged After Positive Vopimetostat Trial Results and Major Capital Raise Publication Date: 10/29/2025 5:59:17 PM, Source: yahoo URL: https://finance.yahoo.com/news/why-tango-therapeutics-tngx-surged-175917875.html?.tsrc=rss - Title: Tango Therapeutics (TNGX) Upgraded to Buy: Here's Why Publication Date: 10/27/2025 4:00:03 PM, Source: yahoo URL: https://finance.yahoo.com/news/tango-therapeutics-tngx-upgraded-buy-160003847.html?.tsrc=rss - Title: Sector Update: Health Care Stocks Softer in Afternoon Trading Publication Date: 10/23/2025 5:47:48 PM, Source: yahoo URL: https://finance.yahoo.com/news/sector-health-care-stocks-softer-174748126.html?.tsrc=rss Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."

$TNGX more I dig into this one more I think a big squeeze can happen…. 1) it’s on the most shorted stocks list with an insane 36 MILLION shares short… huge recipe for a squeeze 2) insanely bullish 225 MILLION private placement at a price of $8.66 which is higher than the current stock price

Does anyone know anything about a drug $TNGX reportedly has in Stage 1 development called something like “Novavyacine”? Sorry I cannot be more specific, but I gather it may be a promising therapeutic for some forms of liver cancer. My sister, with a defective brca gene, is being considered for the trial, but the name doesn’t fit the name of any drug they they have announced a trial. TIA for any responses.

$TNGX sitting below the private placement price interesting watch here

$TNGX and the journey from $7.50 to $10-12 starts.. Strap in folks, gonna be a nice ride with this one...